Alto Neuroscience Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$84.2MTTM through 30 Jun 2026
Free Cash Flow -$68.8MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-41.8%ROE
-34.2%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio14.85x
Net Debt-$177Mnet cash position
Cash & Equivalents$243.7M
Quality Metrics
Altman Z-Score19.35
Piotroski F-Score2 / 9
Earnings-Beat Rate50.0%
Multi-Year Trend
Diluted EPS-$2.32TTMFY2025: $-2.19
Dividend
No dividend
Capital Allocation
R&D Spend$64.9M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.